The recommended starting dose of NAMENDA XR is 7 mg once daily. The recommended target dose is 28 mg once daily.

Namenda package insert / prescribing information for healthcare professionals. Includes: indications, dosage, adverse reactions and pharmacology.

23 мая 2014 г. · CLINICAL NOTES: Memantine is an N-methyl-D-aspartate (NMDA) receptor antagonist FDA approved for use in moderate to severe. Alzheimer's disease.

Treatment of moderate-to-severe dementia. Tablet: 5 mg PO once daily initially; increased by increments of 5 mg/day each week; maintenance target dosage (>5 ...

18 июн. 2010 г. · This new drug application provides for the use of Namenda XR (memantine hydrochloride) 7 ... package insert, text for the patient package insert).

The recommended starting dose of Namenda XR is 7 mg once daily. The dose should be increased in 7 mg increments to a target maximum dose of 28 mg once daily.

MEMANTINE HYDROCHLORIDE extended-release capsules, for oral use. Initial U.S. Approval: 2003. INDICATIONS AND USAGE. Memantine hydrochloride, is a ...

For use in moderate to severe Alzheimer's disease both as monotherapy and with donepezil; may provide small cognitive benefit in mixed dementia and dementia ...

The recommended starting dose of NAMENDA XR is 7 mg once daily. The dose should be increased in 7 mg increments to the recommended maintenance dose of 28 mg ...

Initially 7mg once daily; titrate at intervals of at least 1 week in increments of 7mg to target dose of 28mg once daily. Max 28mg once daily.